Search clinical trials for: PD-L1 high TNBC

Total 25841 results

Sidney Kimmel Comprehensive Cancer Center at Johns...
Fibrolamellar Cancer Foundation; Dracen Pharmaceuticals, Inc.

Recruiting

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Fibrolamellar Hepatocellular Carcinoma

United States
Peking University Cancer Hospital & Institute

Recruiting

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Digestive System Cancers

China
Laekna Limited

Recruiting

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Cervical Cancer | Esophageal Cancer | NSCLC | Solid Tumor | Endometrial Cancer | Gastric and Gastroesophageal Junction Adenocarcinoma

China
Beijing Friendship Hospital

Completed

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Advanced Solid Tumor

China
Merck Sharp & Dohme LLC

Completed

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Lymphoma | Solid Tumors

United States, Korea, Republic of, France, Israel, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Urothelial Cancer
RenJi Hospital

Not yet recruiting

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy (sPLENTY-pc)

Pediatric Cancer | Liver Cancer | Hepatoblastoma | Pediatric Solid Tumor | Transitional Cell Tumor

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

Head and Neck Neoplasms

United States, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Taiwan, Turkey, United Kingdom
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
The Christie NHS Foundation Trust
AstraZeneca

Completed

A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer (PD-RAD)

Non-Small Cell Lung Cancer

United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Renal Cell Carcinoma

United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms

United States, Australia, Hong Kong, Korea, Republic of, New Zealand, Singapore, Taiwan
Merck Sharp & Dohme LLC

Recruiting

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Hodgkin Lymphoma

Australia, Israel, Korea, Republic of, Spain, Poland, Sweden, United Kingdom, Turkey, China, United States, Brazil, Germany, Belgium, France, Switzerland, Canada, Czechia, Chile, Argentina
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Colorectal Neoplasms

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Head and Neck Neoplasms

Poland, Canada, Brazil, Belgium, Japan, United States, Argentina, Australia, Austria, Chile, Colombia, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, Portugal, Russian Federation, Spain, Switzerland, Taiwan, Ukraine, United...
Merck Sharp & Dohme LLC

Completed

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799) (KEYNOTE-799)

Non-small Cell Lung Cancer

United States, Australia, France, Germany, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)

Solid Tumor
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

China, Korea, Republic of, Malaysia, Taiwan
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)

Hepatocellular Carcinoma
National Cancer Institute (NCI)

Recruiting

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Cervical Cancer | Vulvar Cancer | Colon Cancer | Anal Cancer | Vaginal Cancer | Oropharyngeal Cancer | Penile Cancer | HPV | Human Papillomavirus | Neck Cancer

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Spain, Hong Kong, Argentina, China, Netherlands, France, Brazil, Belgium, Canada, Germany, Greece, Italy, Japan, Turkey, Ukraine
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer (PANACEA)

Metastatic Breast Cancer

France, Austria, Belgium, Australia, Italy
Agenus Inc.

Suspended

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Advanced Melanoma

United States, Spain, United Kingdom, France, Germany, Switzerland, Belgium, Italy, Brazil, Russian Federation
Targovax Oy
Agenus Inc.

Withdrawn

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

Melanoma
Groupe Hospitalier Pitie-Salpetriere
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction (CHIMeRA)

Autoimmune Diseases | Endocrine System Diseases | Cancer | Arthritis | Myositis | Neuropathy | Cardiac Disease | Ophthalmopathy

France
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (KEYNOTE-B61)

Renal Cell Carcinoma

Poland, Australia, United States, Canada, France, Hungary, Ireland, Italy, Korea, Republic of, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
National Cancer Institute (NCI)

Recruiting

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Gastroesophageal Junction (GEJ) Cancers | Advanced HNSCC

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Advanced Malignant Skin Neoplasm | Metastatic Malignant Skin Neoplasm

United States
Second Affiliated Hospital of Soochow University

Not yet recruiting

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Carcinoma, Non-Small-Cell Lung | Carcinoma Breast

China
Instituto Nacional de Cancer, Brazil

Completed

Triple-negative Breast Cancer: a New Perspective on Biomarkers (TNBCbrazil)

Triple Negative Breast Cancer | Triple Negative Breast Neoplasms

Brazil
Guohui Li

Recruiting

Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

PD-1 | Immune Related Adverse Events

China
Eastern Hepatobiliary Surgery Hospital

Recruiting

Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC

Gallbladder Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma

China
Radiopharm Theranostics, Ltd

Recruiting

177Lu-anti-PD-L1 sdAb in Metastatic Non-small Cell Lung Cancer

Non Small Cell Lung Cancer | PDL1 Gene Mutation

Australia
Jun Zhang, MD, PhD

Recruiting

Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

NSCLC Stage IV | NSCLC, Recurrent

United States
AstraZeneca

Completed

Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma (PREVAIL)

Urothelial Carcinoma

United States
Shanghai International Medical Center

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

Advanced Solid Tumor | PD-1 Antibody | CAR-T Cells

China
Hunan Province Tumor Hospital

Recruiting

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.

Non-Small Cell Lung Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive

Cervical Cancer

China
Wuxi No. 4 People's Hospital

Unknown

89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors

Solid Tumor, Adult

China
Peter MacCallum Cancer Centre, Australia

Recruiting

Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (BELLA)

Metastatic Triple Negative Breast Cancer

Australia
Second Affiliated Hospital of Soochow University

Not yet recruiting

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Metastatic Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Advanced Malignant Tumors Lymphomas

United States
Olivia Newton-John Cancer Research Institute
Austin Health; Roche Products Pty Limited; Ballarat Health Services

Active, not recruiting

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO)

Follicular Lymphoma

Australia
Hoffmann-La Roche

Active, not recruiting

A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B (Piranga)

Hepatitis B, Chronic

Taiwan, Canada, Korea, Republic of, Thailand, United Kingdom, China, United States, Bulgaria, Spain, New Zealand, Hong Kong, Romania, Chile, France
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
The Second Affiliated Hospital of Harbin Medical...

Unknown

Application Contract Management Mode in Maintaining PD Fluid Balance (ACMMPDFB)

Contract Management PD
Nasser Hanna, M.D.
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Terminated

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Genital Neoplasms, Female | Testicular Neoplasms | Genital Neoplasms, Male | Ovarian Neoplasms | Mediastinal Neoplasms | Germ Cell Neoplasms | Non Seminomatous Germ Cell Tumors

United States

Search clinical trials for: PD-L1 high TNBC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations